Product Information

CICLOPIROX 0.77% TOPICAL SUSP is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.7500 per ML under NDC 45802040049. Its NADAC has been published 665 times since Nov 28, 2013.

FDA first approved this application on Dec 15, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the Ciclopirox Olamine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

CICLOPIROX 0.77% TOPICAL SUSP

Ciclopirox Olamine
$0.7500per ML
High Outlier

Strength

7.7 mg/100mL

NDC

45802040049

Classification

Generic

Dosage Form

SUSPENSION

Route

TOPICAL

Effective Date

8/19/2026

Active Ingredients

CICLOPIROX OLAMINE

Approval Type

Generic (ANDA)

FDA Application

ANDA077676

FDA Approved

12/15/2006

TE Code

AB

On Market Since

12/29/2006

Pharmacological Classes

Decreased DNA Replication
Decreased Protein Synthesis
Decreased RNA Replication
Protein Synthesis Inhibitors

Price Statistics

The NADAC for CICLOPIROX 0.77% TOPICAL SUSP has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 58.9%. The table below summarizes its recorded NADAC range and movement.

Current price$0.7500 per ML
All-time high$1.6970 (Sep 14, 2016)
All-time low$0.3262 (Apr 22, 2015)
52-week high$0.7797
52-week low$0.5857
Median price$0.8371
Average price$0.8307
Largest weekly change+130.8% (May 18, 2016)
Weeks tracked665
Tracking sinceNov 28, 2013

Price History

1W

+12.1%

1M

+12.1%

3M

+28.1%

6M

+11.3%

1Y

-3.8%

3Y

-18.9%

5Y

-31.7%

All

+58.9%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of CICLOPIROX 0.77% TOPICAL SUSP?

The current National Average Drug Acquisition Cost (NADAC) for CICLOPIROX 0.77% TOPICAL SUSP, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.7500 per ML (NDC 45802040049), effective Aug 19, 2026.

How has the price of CICLOPIROX 0.77% TOPICAL SUSP changed over time?

Over the history we have for it, the NADAC for CICLOPIROX 0.77% TOPICAL SUSP has risen 58.9%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for CICLOPIROX 0.77% TOPICAL SUSP?

Since Nov 28, 2013, the NADAC for CICLOPIROX 0.77% TOPICAL SUSP has ranged from a low of $0.3262 (Apr 22, 2015) to a high of $1.6970 (Sep 14, 2016), with a median of $0.8371 per ML.

Are there cheaper alternatives to CICLOPIROX 0.77% TOPICAL SUSP?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CICLOPIROX 0.77% TOPICAL SUSP, is $0.7331 per ML — about 2% below CICLOPIROX 0.77% TOPICAL SUSP.

Who manufactures CICLOPIROX 0.77% TOPICAL SUSP?

CICLOPIROX 0.77% TOPICAL SUSP (NDC 45802040049) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.